BRD9 and acute myeloid leukemia: For AML, we observe a correlation among several lines between sensitivity to BRD9 degrader treatment in terms of inhibition of cell growth and the extent of BRD9 degradation (MV4-11, SKM-1, Kasumi-1 (sensitive) versus HEL, KO52 (resistant)).